[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336436-105":59,"doc-detail-336436-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unique-immune-characteristics-and-differential-anti-pd-1-mediated-reinvigoration-potential-of-cd8-tils-based-on-brca12-mutation-status-in-epithelial-ovarian-cancers-original-research","Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers - Original research","","Background: Investigate distinct immunological characteristics of the tumor immune microenvironment in epithelial ovarian cancer by BRCA1/2 mutation status and differential PD-1 expression levels. Methods: Analyze tumor-infiltrating lymphocytes from newly diagnosed advanced-stage cases and TCGA comparison using multicolor flow cytometry, with in vitro assays to test anti-PD-1 reinvigoration of CD8+ TILs. Results: BRCA1/2-mutated patients show better survival and higher TMB; CD8+ TILs exhibit more severe exhaustion, while anti-PD-1 reinvigoration capacity is greater in non-mutated tumors and PD-1high frequency correlates with reinvigoration. Conclusion: Immune checkpoint blockade may be a promising frontline option for selected BRCA1/2 non-mutated EOC patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unique-immune-characteristics-and-differential-anti-pd-1-mediated-reinvigoration-potential-of-cd8-tils-based-on-brca12-mutation-status-in-epithelial-ovarian-cancers-original-research/336436/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unique-immune-characteristics-and-differential-anti-pd-1-mediated-reinvigoration-potential-of-cd8-tils-based-on-brca12-mutation-status-in-epithelial-ovarian-cancers-original-research/336436.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does BRCA1/2 mutation status affect survival outcomes in epithelial ovarian cancer?","Question",{"text":112,"@type":113},"Patients with BRCA1/2 mutations show better survival outcomes than patients without these mutations, as reported in the study results.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What differences were observed in CD8+ TIL exhaustion between BRCA1/2-mutated and non-mutated tumors?",{"text":117,"@type":113},"CD8+ TILs within BRCA1/2-mutated tumors display characteristics indicating more severe T-cell exhaustion compared with those in BRCA1/2 non-mutated tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"How does anti-PD-1 treatment reinvigorate CD8+ TILs across BRCA1/2 statuses?",{"text":121,"@type":113},"The capacity for anti-PD-1-mediated reinvigoration of CD8+ TILs is significantly greater in BRCA1/2 non-mutated tumors; within the non-mutated group, the frequency of PD-1high CD8+ TILs positively correlates with reinvigoration capacity after anti-PD-1 treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336436,1790491735,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Open access Original research  \n Unique immune characteristics and  \ndifferential anti-PD-1-mediated reinvigoration potential of CD8 + TILs based on BRCA1/2 mutation status in epithelial ovarian cancers  \nJunsik Park  ,1,2 Jung Chul Kim,1,2 Yong Jae Lee,1 Sunghoon Kim,1 Mi-Kyoung Seo,1 Sang Wun Kim,1 Eui-Cheol Shin,3 Jung Yun Lee,1 Su-Hyung Park  3  \nTo cite: Park J, Kim JC, Lee YJ, et al. Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers. Journal for ImmunoTherapy of Cancer 2024;12:e009058 . doi:10 . 1136/ jitc-2024-009058  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-009058](jitc-2024-009058)) .  \nJYL and S-HP are joint senior authors.  \nAccepted 21 June 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Jung Yun Lee; [jungyunlee@yuhs.ac](jungyunlee@yuhs.ac)  \nDr Su-Hyung Park; [park3@kaist.ac.kr](park3@kaist.ac.kr)  \nABSTRACT  \nBackground We aimed to investigate the distinct immunological characteristics of the tumor immune microenvironment in epithelial ovarian cancer (EOC) according to BRCA1/2 mutations status and differential PD-1 expression levels.  \nMethods Tumor-infiltrating lymphocytes (TILs) were collected from patients with newly diagnosed advancedstage EOC (YUHS cohort, n=117) . This YUHS cohort was compared with The Cancer Genome Atlas (TCGA) data for ovarian serous cystadenocarcinoma (n=482), in terms of survival outcomes and immune-related gene profiles according to BRCA1/2 status. We used multicolor flow cytometry to characterize the immune phenotypes and heterogeneity of TILs with or without BRCA1/2 mutations. In vitro functional assays were conducted to evaluate thereinvigorating ability of CD8+ TILs on anti-PD-1 treatment. Results We found that EOC patients with BRCA1/2 mutations (BRCA1/2mt) exhibited better survival outcomes and significantly higher tumor mutation burden (TMB), compared with BRCA1/2 non-mutated (BRCA1/2wt) patients. Furthermore, CD8+ TILs within BRCA1/2mt tumors displayed characteristics indicating more severe T-cell exhaustion than their BRCA1/2wt counterparts. Notably, the capacity for anti-PD-1-mediated reinvigoration of CD8+ TILs was significantly greater in BRCA1/2wt tumors compared with BRCA1/2mt tumors. Additionally, within the BRCA1/2wt group, the frequency of PD-1highCD8+ TILs was positively correlated with thereinvigoration capacity of CD8+ TILs after anti-PD-1 treatment.  \nConclusion Our results highlight unique immune features of CD8+ TILs in EOC and a differential response to antiPD-1 treatment, contingent on BRCA1/2 mutation status. These findings suggest that immune checkpoint blockade may be a promising frontline therapeutic option for selected BRCA1/2wt EOC patients.  \nINTRODUCTION  \nEpithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, causing the  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ The contribution of BRCA1/2 mutations to the tumor immune microenvironment (TIME) in epithelial ovarian cancer (EOC) has not previously been well investigated. The rise of poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors has dramatically shifted the EOC treatment landscape, especially for patients with BRCA1/2 mutations or homologousrecombination deficiency (HRD) . However, at least 50% of EOC patients lack BRCA1/2 mutations and HRD. A deeper understanding of the TIME relative to BRCA1/2 mutation status is crucial to devise new treatment strategies to enhance survival outcomes for patients without BRCA1/2 mutations.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ Here, we highlighted the distinct immunological properties of CD","cbCaikCUcrvHhmKl","https://ap.wps.com/l/cbCaikCUcrvHhmKl","pdf",3319848,12,"English","# Abstract\n# Introduction\n## Background and clinical challenge in epithelial ovarian cancer\n## Role of PARP inhibitors and BRCA1/2 mutations in treatment landscape\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"How does BRCA1/2 mutation status affect survival outcomes in epithelial ovarian cancer?\",\"answer\":\"Patients with BRCA1/2 mutations show better survival outcomes than patients without these mutations, as reported in the study results.\"},{\"question\":\"What differences were observed in CD8+ TIL exhaustion between BRCA1/2-mutated and non-mutated tumors?\",\"answer\":\"CD8+ TILs within BRCA1/2-mutated tumors display characteristics indicating more severe T-cell exhaustion compared with those in BRCA1/2 non-mutated tumors.\"},{\"question\":\"How does anti-PD-1 treatment reinvigorate CD8+ TILs across BRCA1/2 statuses?\",\"answer\":\"The capacity for anti-PD-1-mediated reinvigoration of CD8+ TILs is significantly greater in BRCA1/2 non-mutated tumors; within the non-mutated group, the frequency of PD-1high CD8+ TILs positively correlates with reinvigoration capacity after anti-PD-1 treatment.\"}]","Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers - Original research | PDF",1790015059,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff3cc5eed0ca0698a769f73c8f77cc20.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/357a35bd15717d1f3cc88cd796dd8f7f.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7004501afc4791fda7600dd8c7b779ee.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a79e36a4d67a3da1fc2711ab367d47b3.webp",980,1306]